Prostate Cancer
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) D9723C00001
- Details
ClinicalTrials.gov ID:
NCT06120491
Diagnosis Type:
NA
USOR Number:
- Address
,
P: